Table 1 Summary of included studies
Study ID | Study period | Country | Patients (n) | Patients with MSCC | Age -median (range) | Distribution of involved vertebrae | PSA (ng/ml) -median (range) | Gleason score | Visceral met. | Other bone met. | Involved vertebrae -n | Performance status | Overall survival (median values & OS%) | hormone status | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ju, 2013 [15] | 2002–2011 | USA | 27 | 27 | 65 (46–82) | C-1,CT-3,T-3,TL-7,L-1,LS-1,S-0,C/T/L-5,T/L/S-6 | 50 (0.1–11,900) | median: 8.5 (range, 6–10) | 14 | 26 | NA | KPS: 10–70:19; 80–100:8 | 1)10 (95%CI, 5–16)m; 2)OS%-1/3/6/9/24 m: 96/81/70/62/40 | HR:24; HN:3 | 8 |
Meng, 2016 [16] | 2002–2012 | China | 29 | NA | 71 (59–83) | C-5,T-11,L-12,S-1 | NA | NA | 7 | 10 | NA | KPS: 10–70:26; 80–100:3 | 1)44 (range,1–80)m; 2)OS%-12/24/60 m: 89.7/74.4/19.7 | HR:9; HN:20 | 7 |
Huddart, 1997 [21] | 1984–1992 | UK | 69 | 69 | NA | C-5,T-44,L/S-20 | NA | NA | NA | NA | 1:47; ≥2:20 | NA | 1)4 (range, 0.2–67)m; 2)OS%-24 m: 25 | NA | 8 |
Williams, 2009 [22] | 1993–2005 | USA | 44 | 44 | 68 (51–85) | C-1,CT-1,T-3,TL-11,L-4,LS-1,S-3,C/T/L-15,T/L/S-5 | 27.5 (2.4–1520) | median: 8 (range, 2–10) | 34 | 42 | NA | NA | 1)5 (95%CI, 1–10)m 2)NA | NA | 9 |
Rades, 2012 [23] | 1992–2010 | Germany | 436 | 436 | NA | NA | NA | NA | 100 | 252 | 1–2:178; ≥3:258 | ECOG: 1–2:220; 3–4:216 | 1)NA 2)OS%-6/12 m: 57.3/45.0 | NA | 7 |
Crnalic, 2011 [24] | 2003–2008 | Sweden | 54 | 54 | HR: 72 (54–88); HN: 77 (60–85) | C-1,CT-1,T-43,L-9 | HR: 190 (0.5–5139); HN: 140 (21–3704) | 6:2; 7:15; 8:7; 9:7; 10:3; NA:20 | 12 | 52 | 1:35; 2:17; 3–4:2 | KPS (HR): 10–70:33; 80–100:8 | 1)HR: 5(range, 0–36)m; 2)OS%-1/3/6/12 m: 89/76/59/41 | HR:41 HN:13 | 7 |
Drzymalski, 2010 [25] | 1990–2009 | USA | 333 | 77 | 68 (43–90) | NA | 58.2 (0–19,572) | ≥7: 246 | 37 | 278 | NA | NA | 1)24 (95%CI,21–28)m; 2)OS%-12 m:73 | NA | 8 |
Crnalic, 2012 [14] | 2003–2010 | Sweden | 68 | 68 | HR: 71 (54–88); HN: 77 (60–88) | NA | HR:140 (0.06–5139); HN:147 (21–10,000) | ≤6:3; 7:19; 8:9; 9:9; 10:3; NA: 25 | 17 | NA | NA | KPS: 10–70:47; 80–100:21 | 1)NA 2)OS%-1,3,6,12,24 m: 89.7/72.1/57.4/44.1/23.5 | HR:53; HN:15 | 7 |
Zakaria, 2018 [26] | 2002–2012 | USA | 92 | NA | 73 (51–92) | NA | NA | NA | NA | NA | 1:30; 2:24; 3–4:37 | NA | 1)4.1 (95%CI, 3.3–6.6)m; 2)NA | NA | 6 |
Rades, 2015 [27] | NA | Germany | 243 | 243 | 76 | NA | NA | NA | 65 | 156 | 1–2:94; 3–4:84; ≥5:65 | ECOG: 1–2:107; 3–4:136 | 1)NA; 2)OS%-6/12 m:58.4/46.9 | NA | 6 |
Lehrmann-Lerche, 2019 [28] | 2010–2011 | Denmark | 76 | 76 | 73.2 (50.6–95.8) | C-5, T-53, L-41, S-18 | NA | ≤7:14; 8:18; ≥9:32; NA:12 | NA | 48 | 1:19; 2:19; ≥3:38 | NA | 1)4.9 (95%CI, 3.6–6.2)m; 2)OS%-3/6/12 m: 64/42/21 | NA | 8 |
Weber, 2013 [29] | NA | Germany | 95 | 95 | NA | NA | NA | NA | 69 | NA | 1–2:27; ≥3:68 | ECOG: 1–2:32; 3–4:63 | 1)NA; 2)OS%-6/12 m:57.9/46.3 | NA | 7 |